Previously recorded as Immuron Limited (to 2020)
74 patents currently held
35 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Of the 35 now held by other companies, 11 name Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. as their current owner, and 24 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Dec 2026
Next term end
61
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2039 · High confidence
Also notable
Ends Jun 2029 · High confidence
Also notable
Ends Nov 2028 · High confidence
Also notable
Ends Jan 2029 · High confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Mar 2034 · High confidence
Also notable
Ends Oct 2032 · High confidence
Intracranial Volume Adaptor for Cerebral Blood Flow
US 11,565,091
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039.
Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A
US 8,956,866
The most cited patent in this portfolio, cited by 62 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2029.
Assay and Kit and Device for Removing Amylase from Body Fluids
US 9,297,804
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2028.
Targeting of Innate Immune Response to Tumor Site
US 10,188,741
Granted 2019. Computed term ends 2029.
Attenuated or Inactivated Pathogenic Escherichia Coli for Treating Urogenital Cancer
US 10,918,677
A family of 12 related applications built on the 2021 grant. Protection runs to 2035.
MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
US 10,266,897
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
Pomegranate Oil for Preventing and Treating Neurodegenerative Diseases
US 11,801,220
Granted 2023. Computed term ends 2034.
Allogeneic Tumor Cell Vaccination
US 9,301,998
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Apr 2035 · High confidence
Cited by 26 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 4 to 11, 2026 · next Dec 4
- 3 fees due Jan 2 to 9, 2027 · next Jan 2
- 2 fees due Feb 8 to 27, 2027 · next Feb 8
- 1 fee due Mar 5, 2027The maintenance fee for Large Scale Production of Retinal Pigment Epithelial Cells (US 11,746,324) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 3 fees due Apr 3 to 30, 2027 · next Apr 3
- 2 fees due May 5 to 19, 2027 · next May 5
- 3 fees due Jun 5 to 26, 2027 · next Jun 5
- 3 fees due Jul 9 to 26, 2027 · next Jul 9
- 1 fee due Sep 29, 2027The maintenance fee for Assay and Kit and Device for Removing Amylase from Body Fluids (US 9,297,804) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 3 fees due Oct 5 to 14, 2027 · next Oct 5
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
- 2 terms have ended since Aug 23, 2026
- Sep 13 US 11,439,587 Injectable Implants · lapsed on the fee record
- Sep 4 US 10,064,927 Allogeneic Tumor Cell Vaccination · lapsed on the fee record
What they patent
The largest of its 61 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,597,947 | Undifferentiated Stem Cell Culture Systems In force · High confidence | In force | High confidence | |
| US 8,535,645 | Antimicrobial Nanoparticulate Additives Forming Non-Leachable Sustained Antimicrobial Polymeric Compositions held by Hadasit Medical Research Services & Development Limited and Yissum Research Development Company of the Hebrew Universiry of Jerusalem In force · High confidence | In force | High confidence | |
| US 9,297,804 | Assay and Kit and Device for Removing Amylase from Body Fluids held by Yissum, Research Development Company of the Hebrew University of Jerusalem Ltd. and Hadasit Medical Research Services and Development Ltd. In force · High confidence | In force | High confidence | |
| US 10,188,741 | Targeting of Innate Immune Response to Tumor Site In force · High confidence | In force | High confidence | |
| US 8,895,054 | Methods for Joint Lubrication and Cartilage Wear Prevention Making Use of Glycerophospholipids held by Technion Research and Development Foundation Ltd., Hadasit Medical Research Services & Development Limited and Yissum Research Development Company of the Hebrew University of Jerusalem In force · High confidence | In force | High confidence | |
| US 8,956,866 | Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A In force · High confidence | In force | High confidence | |
| US 8,735,149 | Motor Neurons Developed from Stem Cells In force · High confidence | In force | High confidence | |
| US 9,072,737 | tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS In force · High confidence | In force | High confidence | |
| US 10,314,873 | Method of Treatment of Diseases Using Hoodia Extracts held by Hadasit Medical Research Services & Development Ltd. and Desert Labs Agriculture Cooperative Association Ltd. In force · High confidence | In force | High confidence | |
| US 10,117,930 | Anti-LPS Enriched Immunoglobulin Preparations For The Treatment And/Or Prophylaxis Of A Pathologic Disorder In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 74: 35 patents in force now held by others · 79 patents ended · 73 applications pending · 135 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.